Evenity (Romosozumab) Titration in Renal Impairment: What Women Need to Know

What Is Romosozumab and Why Does Kidney Function Matter?

Romosozumab is a monoclonal antibody that blocks sclerostin, a protein made in bone that normally suppresses new bone formation. By inhibiting sclerostin, romosozumab simultaneously increases bone formation and reduces bone resorption, a dual action no other approved osteoporosis drug shares. The FDA approved it in April 2019 specifically for postmenopausal women with osteoporosis at high or very high fracture risk.

Kidney function changes almost everything about how this drug behaves in your body. The kidneys regulate calcium balance, activate vitamin D, and clear some drug metabolites. When kidney function drops, calcium can fall dangerously after each injection, and the baseline cardiovascular risk that already carries an FDA boxed-adjacent warning becomes even harder to manage. Understanding exactly where the evidence is solid, and where it runs out, is essential before you and your clinician decide whether romosozumab is the right choice.

How the Kidneys Interact With Bone-Active Drugs

Chronic kidney disease (CKD) disrupts the parathyroid hormone-vitamin D-calcium axis at every level. Secondary hyperparathyroidism is nearly universal by CKD Stage 3b. A 2020 analysis in the Journal of Bone and Mineral Research confirmed that sclerostin levels are elevated in CKD patients compared with the general population, which is one reason some researchers hoped romosozumab might be particularly effective in this group. The catch is that the same calcium-phosphate dysregulation that raises sclerostin also creates the conditions for severe hypocalcemia once sclerostin is blocked and bone formation suddenly accelerates.

Sclerostin Biology in Women With CKD

Women with CKD have sex-specific bone loss patterns that differ from men: estrogen deficiency after menopause compounds the high-turnover renal osteodystrophy seen in CKD, producing a mixed picture that makes fracture risk especially high. A registry study published in Osteoporosis International found that postmenopausal women on dialysis have hip fracture rates 4 to 17 times higher than age-matched women with normal kidney function, depending on the country. That risk context is why nephrologists and gynecologists increasingly need to work together on bone health decisions for women with CKD.

The FDA-Approved Dose and What "No Adjustment" Really Means

The approved romosozumab dose is 210 mg administered as two simultaneous 105 mg subcutaneous injections once monthly for 12 months, per the current FDA prescribing information. The label states no dose adjustment is required based on renal function. That sentence reassures many clinicians, but it deserves careful unpacking.

What the Pharmacokinetic Data Actually Show

In the population pharmacokinetic analysis that supported the label, romosozumab exposure (AUC and Cmax) did not differ meaningfully across mild CKD (eGFR 60-89) and moderate CKD (eGFR 30-59) compared with women with normal kidney function. Monoclonal antibodies are not renally cleared in the same way small molecules are. They are catabolized by proteolytic degradation throughout body tissues, so GFR has little direct effect on drug exposure. This is why the dose number itself does not change.

What does change is the safety context. The label is explicit: women with severe renal impairment (eGFR <30) or on dialysis were not studied in sufficient numbers to draw firm conclusions, and the hypocalcemia sections of the prescribing information apply most forcefully to this group.

CKD Stage-by-Stage Breakdown

| CKD Stage | eGFR (mL/min/1.73 m²) | Dose Adjustment | Key Monitoring | |---|---|---|---| | G1 (Normal) | ≥90 | None | Standard Ca/VitD repletion | | G2 (Mild decrease) | 60-89 | None | Serum Ca before each dose | | G3a (Mild-moderate) | 45-59 | None | Serum Ca, PTH, 25-OHD | | G3b (Moderate-severe) | 30-44 | None, but heightened caution | Ca, PTH, phosphate; nephrology co-management | | G4 (Severe) | 15-29 | No label guidance; use with extreme caution | Minimal trial data; case-by-case | | G5 / Dialysis | <15 | Not studied; generally avoid | Insufficient safety data |

Evidence From the Key Trials: Who Was Actually Studied?

The two trials that built the romosozumab evidence base are FRAME and ARCH. Understanding their populations tells you directly how well the trial data applies to women with significant kidney disease.

FRAME Trial

The FRAME trial enrolled 7,180 postmenopausal women with a T-score of -2.5 to -3.5 at the lumbar spine or total hip and randomized them to romosozumab 210 mg monthly or placebo for 12 months, followed by denosumab in both arms. At 12 months, romosozumab reduced new vertebral fractures by 73% compared with placebo. At 24 months (after the denosumab extension), the reduction was 75%. These are the numbers that drove FDA approval.

The problem for women with advanced CKD: the trial excluded women with a creatinine clearance below 35 mL/min. Mild-to-moderate CKD was present in a subset of participants, but the trial was not powered to report fracture outcomes specifically in CKD subgroups.

ARCH Trial

The ARCH trial compared romosozumab with alendronate in 4,093 postmenopausal women at very high fracture risk (prior fracture plus low T-score). Romosozumab followed by alendronate reduced clinical fractures by 27% versus alendronate alone over 24 months. ARCH had a similar renal exclusion criterion (serum creatinine above 2.0 mg/dL, roughly an eGFR below 30-35 in most postmenopausal women). The ARCH trial also identified the cardiovascular safety signal: serious cardiovascular events occurred in 2.5% of the romosozumab group versus 1.9% in the alendronate group during the 12-month treatment phase, leading to the current prescribing warning.

A practical framework for women with CKD considering romosozumab: think of the evidence as a confidence gradient. At CKD Stage 1-3a, the pharmacokinetic data are reassuring and the safety profile matches the label. At Stage 3b, the drug exposure is similar but hypocalcemia risk rises enough to require pre-treatment calcium optimization and more frequent labs. At Stage 4, you are operating outside the trial populations with minimal published case series to guide decisions, and the conversation should include a nephrologist.

Hypocalcemia: The Most Urgent Safety Issue in Renal Impairment

Hypocalcemia is the most common serious adverse effect of romosozumab in women with CKD, and it is preventable in most cases with proper preparation. The FDA label requires that hypocalcemia be corrected before starting romosozumab and that all patients receive adequate calcium and vitamin D throughout treatment.

Why CKD Makes Hypocalcemia More Likely

When romosozumab blocks sclerostin, bone formation ramps up rapidly in the first few weeks after each injection. That sudden surge in bone matrix mineralization demands large amounts of calcium from the bloodstream. In a woman with normal kidneys, the kidney responds by activating more vitamin D, which pulls calcium from the gut. In CKD, that compensatory pathway is blunted or absent. The result is a steeper and more sustained drop in serum calcium after each injection.

Pre-treatment Calcium and Vitamin D Protocol

Clinicians managing women with CKD Stage 3b or higher on romosozumab typically follow a stepped protocol before the first injection:

• Confirm serum 25-hydroxyvitamin D is at least 30 ng/mL (75 nmol/L); supplement if below this threshold and recheck before proceeding.
• Confirm serum corrected calcium is within the normal reference range for the laboratory.
• Start oral calcium supplementation (commonly 1,000 to 1,200 mg elemental calcium daily in divided doses) at least two weeks before the first injection.
• In CKD Stage 3b and beyond, active vitamin D (calcitriol or alfacalcidol) may be preferred over native vitamin D because the kidney cannot activate native vitamin D efficiently.

A clinical guidance statement from the American Society of Nephrology on CKD-mineral and bone disorder emphasizes that pre-treatment optimization of mineral metabolism is non-negotiable before any anabolic bone agent in this population.

Monitoring Schedule After Each Injection

Post-injection serum calcium should be checked at approximately 2 weeks after the first dose (when the nadir typically occurs) and before each subsequent monthly injection. Women with Stage 3b CKD warrant a full panel: calcium, phosphate, PTH, and 25-OHD at baseline and every 3 months during the 12-month course.

Cardiovascular Risk: The Boxed Warning Women With CKD Must Understand

The romosozumab label carries a boxed warning stating it may increase the risk of myocardial infarction, stroke, and cardiovascular death. Women with CKD already carry a substantially elevated baseline cardiovascular risk. CKD Stage 3-4 is itself classified as a high-risk cardiovascular state by major cardiology guidelines, so the combination demands explicit risk-benefit discussion.

The ARCH data showed the cardiovascular signal was concentrated in the first 12 months of romosozumab exposure; it did not persist into the alendronate extension phase. No mechanism has been confirmed, though sclerostin may have a protective role in vascular calcification, and blocking it could theoretically accelerate vascular calcium deposition, an area of active research particularly relevant to CKD patients who already have high vascular calcification burdens.

A 2022 observational cohort study in the Journal of the American Society of Nephrology found that CKD patients have coronary artery calcium scores roughly three times higher than age-matched controls with normal kidney function. This background risk profile makes the cardiovascular warning in the romosozumab label more consequential in this group than in the general postmenopausal population.

Do not use romosozumab if you have had a myocardial infarction or stroke within the past 12 months. This contraindication applies regardless of kidney function but is especially pertinent given CKD's cardiovascular profile.

Pregnancy, Lactation, and Contraception: Required Reading

Romosozumab is not approved for use in premenopausal women and should not be used during pregnancy.

Pregnancy Safety Data

Animal reproductive studies showed fetal harm at doses that produced exposures roughly 19 times the clinical human exposure. The FDA prescribing information classifies romosozumab as contraindicated in pregnancy based on these animal data. There are no adequate human pregnancy studies. Because the drug is approved only for postmenopausal women, human pregnancy exposure has been rare; no strong registry data exist.

If a woman of reproductive potential were to receive romosozumab off-label, reliable contraception during treatment and for a defined washout period would be mandatory. The half-life of romosozumab is approximately 6.4 days, meaning the drug clears within about 6 to 8 weeks, but given the lack of human reproductive safety data, extreme caution is warranted.

Lactation

No data exist on the presence of romosozumab in human milk, its effect on milk production, or its effect on a breastfed infant. Given that the approved population is postmenopausal women, lactation co-exposure is not a practical clinical scenario. If it were to arise in an off-label context, the risk-benefit assessment would need to account for the absence of any safety data.

Life Stage Summary for Reproductive-Age and Perimenopausal Women

Romosozumab has not been studied in premenopausal women or in perimenopause. Bone loss accelerates in the two to three years before the final menstrual period, and some perimenopausal women have T-scores in the osteoporotic range, but the trial data do not support romosozumab use before confirmed menopause. ACOG recommends bisphosphonates as the first-line pharmacologic option when treatment is needed in premenopausal or perimenopausal women, with specialist referral for complex cases.

Who This Drug Is Right For (and Who It Is Not)

Women Most Likely to Benefit

• Postmenopausal women with a T-score at or below -2.5 at the spine or hip, plus at least one additional high-risk feature (prior fragility fracture, very low T-score, age above 70, multiple falls).
• Women who have already fractured on or are unable to tolerate oral bisphosphonates.
• Women with CKD Stage 1 through 3a who have corrected calcium, adequate vitamin D status, and no history of MI or stroke in the past 12 months.
• Women with CKD Stage 3b who have undergone full nephrology co-evaluation, mineral metabolism optimization, and explicit cardiovascular risk review.

Women for Whom the Risk-Benefit Ratio Is Unfavorable

• Any woman with an MI or stroke within the past 12 months (contraindicated by label).
• Women with uncorrected hypocalcemia.
• Women with CKD Stage 4 or 5: the evidence base is essentially absent, and safer alternatives with more CKD-specific data (such as denosumab with careful calcium monitoring, or zoledronic acid in appropriate eGFR ranges) should be explored first.
• Premenopausal women, including those still having periods or in early perimenopause.
• Women who are pregnant or planning pregnancy.

CKD Stage 3b: The Gray Zone

CKD Stage 3b (eGFR 30-44) represents the clinically most contested territory. Published case series are small, including a 2021 case report series in Osteoporosis International describing successful romosozumab use in four postmenopausal women with eGFR values between 30 and 45, with no severe hypocalcemia when active vitamin D was pre-loaded. These reports are encouraging but cannot substitute for trial-level evidence. Use in this range should be treated as a considered, documented, shared decision rather than a routine prescription.

Sequencing After Romosozumab: Why It Matters Even More in CKD

Romosozumab produces its bone density gains primarily during the 12-month treatment window. The FRAME extension data show that without antiresorptive therapy afterward, a substantial portion of the bone density gained is lost within 12 months of stopping. This means sequential antiresorptive therapy is not optional.

Antiresorptive Options in CKD After Romosozumab

For women with CKD, the post-romosozumab sequencing choice is constrained:

Denosumab: Works across all eGFR ranges because it is not renally cleared. However, stopping denosumab without subsequent bisphosphonate consolidation leads to rebound vertebral fractures, a risk amplified in women with CKD who may already have fragile vertebrae. Denosumab after romosozumab requires a committed long-term plan and carries its own hypocalcemia risk in CKD.

Bisphosphonates (oral or IV): Oral bisphosphonates are generally not recommended below eGFR 35, and IV zoledronic acid is typically avoided below eGFR 35 as well, given accumulation risk. Women with mild-to-moderate CKD (eGFR 35 to 60) can often receive zoledronic acid with monitoring, making it a viable post-romosozumab consolidation option in that range.

A 2023 Endocrine Society Clinical Practice Guideline on osteoporosis in CKD recommends individualized sequencing with nephrology input for women at CKD Stage 3b and beyond, noting that no single algorithm covers all clinical situations.

Monitoring Checklist for Women With CKD on Romosozumab

A practical visit-by-visit monitoring plan for clinicians and women alike:

Before the first injection:

• Serum calcium (corrected), phosphate, PTH, 25-OHD, creatinine/eGFR, albumin.
• Cardiovascular history review (MI, stroke within 12 months is a hard stop).
• DXA baseline (spine and hip T-scores).
• Start calcium supplementation and correct vitamin D deficiency.

2 weeks after injection 1:

• Serum calcium. Symptomatic hypocalcemia (tingling, muscle cramps, tetany) is an emergency.

Before each subsequent monthly injection:

• Serum calcium. Hold the dose if calcium is below the normal range and recheck after optimization.

Every 3 months during the 12-month course:

• Full mineral metabolism panel (Ca, phosphate, PTH, 25-OHD).

At month 12 (end of romosozumab course):

• Repeat DXA.
• Plan and initiate antiresorptive sequencing.
• Reassess eGFR to inform antiresorptive choice.

A Note on the Evidence Gap for Women With Advanced CKD

Women have historically been under-represented in osteoporosis-CKD trial populations, and women with advanced CKD are doubly excluded: first by the sex-skewed enrollment in nephrology trials, then by the renal exclusion criteria in osteoporosis trials. The data reviewed in this article are largely extrapolated from trials in postmenopausal women with mild-to-moderate kidney disease. For CKD Stage 4 and 5, you are working from pharmacokinetic reasoning, small case series, and biological plausibility rather than direct fracture-outcome evidence. Your clinician should name this uncertainty explicitly when discussing romosozumab as an option.